Press

Mind Cure Enters Into Binding Letter of Intent with LNG Energy Group

Dec 15 • 6 min read

Mind Cure Health Inc. (CSE: MCUR | OTCQB: MCURF | FRA: 6MH) today announced that it has signed a binding Letter of Intent with LNG Energy Group Inc. pursuant to which the Company will acquire all of the issued and outstanding securities in the capital of LNG Energy by way of a business combination transaction….

Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis

Dec 15 • 3 min read

Algernon Pharmaceuticals Inc. (CSE: AGN | FRANKFURT: AGW0 | OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that the United States Food and Drug Administration (“U.S. FDA”) has granted Orphan Drug Designation (ODD) to Ifenprodil as a treatment for Idiopathic Pulmonary Fibrosis (IPF). Ifenprodil is the sole active ingredient in…

Mindbloom Announces Rollout of Ketamine Telehealth Employee Benefits Program with Kennedy Care, 15Five

Dec 14 • 3 min read

Mindbloom, the world’s largest provider of ketamine therapy, announced Wednesday the launch of a new employee benefits partnership with Kennedy Care, a leader in home care services across Michigan and Northern Ohio. As of November, Kennedy Care employees can access at-home ketamine therapy through Mindbloom. “I’m beyond thrilled that Mindbloom has agreed to work with my…

Core One Labs : Subsidiary Vocan Biotechnologies Achieves Development Milestones

Dec 14 • 2 min read

Core One Labs Inc. (CSE: COOL | OTCQB: CLABF | Frankfurt: LD6, WKN: A3CSSU) the Company is pleased to announce that its wholly-owned subsidiary, Vocan Biotechnologies Inc., has successfully achieved two critical development milestones, the successful synthesis of psilocybin and the filing of a patent application for the process with the United States Patent and Trademark Office. Achievement of…

Numinus to Participate in the KCSA Mental Health Virtual Investor Conference on December 15, 2022

Dec 14 • 2 min read

Numinus Wellness Inc. (TSX: NUMI | OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO of Numinus, will present at the KCSA Mental Health Investor Conference to be held at VirtualInvestorConferences.com on Thursday, December 15, 2022 at 12:30 p.m. ET / 9:30 a.m. PT. This will be a live, interactive…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421